Marshall Wace, LLP Aadi Bioscience, Inc. Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.97 - $5.41 $42,158 - $115,774	21,400 New	21,400 $43,000
Q4 2022 Feb 14, 2023	BUY	$11.99 - $14.5 $185,833 - $224,735	15,499 New	15,499 $198,000
Q2 2022 Aug 15, 2022	SELL	$11.57 - $17.92 $827,497 - $1.28 Million	-71,521 Reduced 78.52%	19,564 $242,000
Q1 2022 May 16, 2022	BUY	$16.65 - $24.97 $1.03 Million - $1.55 Million	61,912 Added 212.22%	91,085 $1.54 Million
Q4 2021 Feb 14, 2022	BUY	$19.32 - $29.02 $563,622 - $846,600	29,173 New	29,173 $704,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $71.2M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.